| | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
Sanofi, after R&D setback, lends a hand to vaccine rival Pfizer for coronavirus shot production Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data' Here's how the NFL tackled the spread of COVID-19 among players, staff Regeneron pitches COVID-19 antibody cocktail for 'passive vaccination' with fresh trial data Lilly antibody combo slashed COVID-19 deaths, hospitalizations in high-risk patients Kaufman Hall: Hospitals close out 2020 with declining margins and higher expenses due to COVID-19 Johnson & Johnson is 'comfortable' meeting coronavirus vaccine delivery promises, CFO says Abbott's Panbio antigen test obtains new European approvals for mass COVID-19 screening Healthcare roundup: Lyft urges CMS to consider transportation challenges to vaccine sites Emergent BioSolutions unveils 7th pandemic CDMO contract, this time for Humanigen's late-stage antibody hopeful Featured Story | By Eric Sagonowsky Following its midstage coronavirus R&D setback, vaccine giant Sanofi is still looking for ways to help in the world’s effort to beat back the pandemic. It’s teaming up with leading vaccine players Pfizer and BioNTech to produce 100 million doses of the rival vaccine—even as Sanofi works to push its own programs through clinical testing. read more |
| |
|---|
|
Top Stories By Ben Adams While the world struggles with two-shot vaccine production as a handful of pharma companies try to make enough for almost the entire global population, a single-dose option from Johnson & Johnson has become a major hope in the fight against COVID-19. read more By Heather Landi During a global pandemic, the NFL got all 256 regular-season games played within 17 weeks in 2020. Despite the close physical contact among players on the field, the NFL was able to reduce the spread of the virus. Here are lessons learned from the league's mitigation strategies that can be applied to workplaces and schools. read more By Arlene Weintraub A preliminary readout from a phase 3 trial of Regeneron's antibody cocktail showed the drug halved the rate of infection and prevented symptoms completely in people at high risk of contracting COVID-19. The cocktail could offer an alternative to vaccines, which are in short supply, the company argued. read more By Eric Sagonowsky Amid new worries about COVID-19 vaccine supplies, monoclonal antibodies—such as those from Eli Lilly and Regeneron—could be important stopgaps to reduce deaths and hospitalizations until vaccinations gain steam. And Lilly is touting data showing two of its antibodies did just that in high-risk patients. read more By Robert King The hospital industry closed out 2020 with declines in financial performance due to the pandemic, according to a new report from Kaufman Hall that doesn't believe things will get immediately better for hospitals in 2021. read more By Eric Sagonowsky As the world awaits J&J's phase 3 COVID-19 vaccine data, the company is prepping for regulatory filings and global rollouts. Orders for hundreds of millions of doses are pending. But at a time when rivals face manufacturing and logistics hurdles, a top exec said J&J can comfortably meet its 2021 supply commitments. read more By Conor Hale Abbott has received new COVID-19 diagnostic approvals in Europe for its rapid Panbio antigen test, clearing it for self-performed screening under supervision, as well as widespread use by people who have not shown symptoms of the disease. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner Manufacturing powerhouse Emergent BioSolutions unveiled its seventh COVID-19 CDMO tie-up Monday, this time to help crank out Humanigen’s late-stage antibody hopeful lenzilumab. Emergent will hustle along fill-finish work on lenzilumab at its Camden plant in Baltimore, boosting supplies ahead of a possible emergency nod early this year. read more |
